Spinraza: Additional Ph III ENDEAR data

Additional data from the 13-month, double-blind, international Phase III ENDEAR trial in 121 patients with infantile-onset SMA showed that intrathecal Spinraza met the co-primary endpoint of reducing the percentage of

Read the full 301 word article

User Sign In